tradingkey.logo

Eli Lilly Shares Plunge 10% After Data for Experimental Oral Weight-Loss Drug

TigerAug 7, 2025 10:30 AM

Eli Lilly Shares Plunge 10% After Data for Experimental Oral Weight-Loss Drug

Lilly's Oral GLP-1, Orforglipron, Delivers Weight Loss of up to an Average of 27.3 Lbs in First of Two Pivotal Phase 3 Trials in Adults With Obesity

Eli Lilly Attain-1 Trial Shows Orforglipron's Efficacy and Safety at 72 Weeks

Eli Lilly to Submit Orforglipron for Regulatory Review by Year-End

Eli Lilly Orforglipron's Safety Profile Consistent With GLP-1 Agonists

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI